R&D Pipeline

Products and New Molecular Entities

Boehringer Ingelheim has brought a range of successful products from own drug discovery to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US Dollar or have blockbuster potential. Continuously, our improvement initiatives have increased our research productivity and have resulted in a well-balanced pipeline showing a substantial number of new molecular entities and a high share of products in late phase development.

Successful Products from our own Research & Development

Product name First launch Active ingredient Indication
Pradaxa® 2008 dabigatran etexilate Prevention of venous thromboembolic events in adults
Spiriva®
Respimat Soft Mist™ Inhaler

Spiriva®		 2007



2002		 tiotropium COPD
Micardis® 1998 telmisartan Essential hypertension
Sifrol® / Mirapex® / Mirapexin® 2006

1997		 pramipexole Restless legs syndrome (RLS)

Parkinson's disease
Viramune® 1996 nevirapine HIV/AIDS

Promising Compounds in our Pipeline - Examples

Clinical phase Compound* Indication Therapeutic principle Mode of action
Phase III Flibanserin Hypoactive sexual desire disorder (HSDD) in pre-menopausal women Serotonin receptor agonist and antagonist Neurotransmitter modulator
Phase III Ondero® (linagliptin) Diabetes mellitus type II DPP-IV inhibition Dipeptidylpeptidase-IV inhibitor
Phase III BIBF 1120 (Vargatef®) Primary indication:
Non-small cell lung cancer/NSCLC		 Angiogenesis inhibition Triple angiokinase inhibitor acting simultaneously on VEGFR, FGFR, PDGFR
Phase III BIBW 2992 (Tovok®) Primary indication:
Non-small cell lung cancer/NSCLC		 Signal transduction inhibition Dual irreversible EGFR/HER2 inhibitor
Phase II BI 6727 Variety of cancer types Cell-cycle kinase inhibition PLK-1 inhibitors
Phase I New compound Variety of cancer types Mitotic checkpoint inhibitor

* These are investigational agents; their safety and efficacy have not yet been established.

Status: 21 April 2009

back to top